FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148348570> ?p ?o ?g. }

• W2148348570 endingPage "172" @default.
• W2148348570 startingPage "163" @default.
• W2148348570 abstract "Background Terfenadine, astemizole, cetirizine, and loratadine are compared in their abilities to produce relief of symptoms of allergic rhinitis. Objective The aim of this study was to compare the onset of action and efficacy of the study medications. Methods One hundred eleven ragweed-sensitive subjects were primed with pollen in the Environmental Exposure Unit. Study entry required adequate symptoms over a 3-hour exposure to 5,000 ± 300 grains/m3 of ragweed pollen. On the test day, subjects were given a single dose of either terfenadine 60 mg (22), astemizole 10 mg (22), cetirizine 10 mg (23), loratadine 10 mg (22), or placebo (22) when sufficiently symptomatic after a 60-minute exposure. Allergen levels were maintained and symptoms recorded every 30 minutes. Results Proportions of subjects with clinically important relief were cetirizine, 69.6%; terfenadine, 54.5%; loratadine, 50.0% astemizole, 40.9%; and placebo, 31.8% but differences weren't significant between treatment groups (P = .119). Survival curves for times to onset of clinically important relief for the four treatment groups were not different (P = .119). Subjects realizing definitive relief were cetiriazine, 65.2%; terfenadine, 45.5%; loratadine, 31.8%; placebo, 27.3%; and astemizole, 22.7% (P = .023). Survival analysis of onset time for definitive relief found significant differences (P = .010). The ranking was cetirizine to terfenadine to loratadine to astemizole (quickest to slowest). Global evaluation based on subject willingness to take the medication again yielded percentages: cetirizine, 82.6%; terfenadine, 66.7%; astemizole, 63.6%; loratadine, 40.9%; and placebo, 36.4% (P = .036). Conclusion Cetirizine and terfenadine continuously ranked higher in terms of onset of action and efficacy, while loratadine and astemizole ranked lower. Significance was detected in definitive relief and relative efficacy. Terfenadine, astemizole, cetirizine, and loratadine are compared in their abilities to produce relief of symptoms of allergic rhinitis. The aim of this study was to compare the onset of action and efficacy of the study medications. One hundred eleven ragweed-sensitive subjects were primed with pollen in the Environmental Exposure Unit. Study entry required adequate symptoms over a 3-hour exposure to 5,000 ± 300 grains/m3 of ragweed pollen. On the test day, subjects were given a single dose of either terfenadine 60 mg (22), astemizole 10 mg (22), cetirizine 10 mg (23), loratadine 10 mg (22), or placebo (22) when sufficiently symptomatic after a 60-minute exposure. Allergen levels were maintained and symptoms recorded every 30 minutes. Proportions of subjects with clinically important relief were cetirizine, 69.6%; terfenadine, 54.5%; loratadine, 50.0% astemizole, 40.9%; and placebo, 31.8% but differences weren't significant between treatment groups (P = .119). Survival curves for times to onset of clinically important relief for the four treatment groups were not different (P = .119). Subjects realizing definitive relief were cetiriazine, 65.2%; terfenadine, 45.5%; loratadine, 31.8%; placebo, 27.3%; and astemizole, 22.7% (P = .023). Survival analysis of onset time for definitive relief found significant differences (P = .010). The ranking was cetirizine to terfenadine to loratadine to astemizole (quickest to slowest). Global evaluation based on subject willingness to take the medication again yielded percentages: cetirizine, 82.6%; terfenadine, 66.7%; astemizole, 63.6%; loratadine, 40.9%; and placebo, 36.4% (P = .036). Cetirizine and terfenadine continuously ranked higher in terms of onset of action and efficacy, while loratadine and astemizole ranked lower. Significance was detected in definitive relief and relative efficacy." @default.
• W2148348570 created "2016-06-24" @default.
• W2148348570 creator A5016112377 @default.
• W2148348570 creator A5025685482 @default.
• W2148348570 creator A5050170654 @default.
• W2148348570 creator A5078457202 @default.
• W2148348570 creator A5080896798 @default.
• W2148348570 date "1997-08-01" @default.
• W2148348570 modified "2023-09-27" @default.
• W2148348570 title "Onset of Action and Efficacy of Terfenadine, Astemizole, Cetirizine, and Loratadine for the Relief of Symptoms of Allergic Rhinitis" @default.
• W2148348570 cites W1996577039 @default.
• W2148348570 cites W2023671946 @default.
• W2148348570 cites W2064442597 @default.
• W2148348570 doi "https://doi.org/10.1016/s1081-1206(10)63104-3" @default.
• W2148348570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9291422" @default.
• W2148348570 hasPublicationYear "1997" @default.
• W2148348570 type Work @default.
• W2148348570 sameAs 2148348570 @default.
• W2148348570 citedByCount "69" @default.
• W2148348570 countsByYear W21483485702012 @default.
• W2148348570 countsByYear W21483485702013 @default.
• W2148348570 countsByYear W21483485702015 @default.
• W2148348570 countsByYear W21483485702018 @default.
• W2148348570 countsByYear W21483485702019 @default.
• W2148348570 countsByYear W21483485702020 @default.
• W2148348570 countsByYear W21483485702022 @default.
• W2148348570 crossrefType "journal-article" @default.
• W2148348570 hasAuthorship W2148348570A5016112377 @default.
• W2148348570 hasAuthorship W2148348570A5025685482 @default.
• W2148348570 hasAuthorship W2148348570A5050170654 @default.
• W2148348570 hasAuthorship W2148348570A5078457202 @default.
• W2148348570 hasAuthorship W2148348570A5080896798 @default.
• W2148348570 hasConcept C10335311 @default.
• W2148348570 hasConcept C126322002 @default.
• W2148348570 hasConcept C142724271 @default.
• W2148348570 hasConcept C170493617 @default.
• W2148348570 hasConcept C203014093 @default.
• W2148348570 hasConcept C204787440 @default.
• W2148348570 hasConcept C207480886 @default.
• W2148348570 hasConcept C27081682 @default.
• W2148348570 hasConcept C2776129107 @default.
• W2148348570 hasConcept C2776880894 @default.
• W2148348570 hasConcept C2776885963 @default.
• W2148348570 hasConcept C2779303165 @default.
• W2148348570 hasConcept C2779463773 @default.
• W2148348570 hasConcept C2780734495 @default.
• W2148348570 hasConcept C42219234 @default.
• W2148348570 hasConcept C46821324 @default.
• W2148348570 hasConcept C71924100 @default.
• W2148348570 hasConcept C98274493 @default.
• W2148348570 hasConceptScore W2148348570C10335311 @default.
• W2148348570 hasConceptScore W2148348570C126322002 @default.
• W2148348570 hasConceptScore W2148348570C142724271 @default.
• W2148348570 hasConceptScore W2148348570C170493617 @default.
• W2148348570 hasConceptScore W2148348570C203014093 @default.
• W2148348570 hasConceptScore W2148348570C204787440 @default.
• W2148348570 hasConceptScore W2148348570C207480886 @default.
• W2148348570 hasConceptScore W2148348570C27081682 @default.
• W2148348570 hasConceptScore W2148348570C2776129107 @default.
• W2148348570 hasConceptScore W2148348570C2776880894 @default.
• W2148348570 hasConceptScore W2148348570C2776885963 @default.
• W2148348570 hasConceptScore W2148348570C2779303165 @default.
• W2148348570 hasConceptScore W2148348570C2779463773 @default.
• W2148348570 hasConceptScore W2148348570C2780734495 @default.
• W2148348570 hasConceptScore W2148348570C42219234 @default.
• W2148348570 hasConceptScore W2148348570C46821324 @default.
• W2148348570 hasConceptScore W2148348570C71924100 @default.
• W2148348570 hasConceptScore W2148348570C98274493 @default.
• W2148348570 hasIssue "2" @default.
• W2148348570 hasLocation W21483485701 @default.
• W2148348570 hasLocation W21483485702 @default.
• W2148348570 hasOpenAccess W2148348570 @default.
• W2148348570 hasPrimaryLocation W21483485701 @default.
• W2148348570 hasRelatedWork W141509808 @default.
• W2148348570 hasRelatedWork W2016523948 @default.
• W2148348570 hasRelatedWork W2061025681 @default.
• W2148348570 hasRelatedWork W2097050108 @default.
• W2148348570 hasRelatedWork W2129867925 @default.
• W2148348570 hasRelatedWork W2148348570 @default.
• W2148348570 hasRelatedWork W2161927647 @default.
• W2148348570 hasRelatedWork W2401629534 @default.
• W2148348570 hasRelatedWork W74436779 @default.
• W2148348570 hasRelatedWork W1759177440 @default.
• W2148348570 hasVolume "79" @default.
• W2148348570 isParatext "false" @default.
• W2148348570 isRetracted "false" @default.
• W2148348570 magId "2148348570" @default.
• W2148348570 workType "article" @default.